Four drug programs — Ifinatamab Deruxtecan, Ziihera, Gedatolisib, and Roche's Tecentriq — face concurrent FDA decisions in H2 2026, compressing years of binary event risk into a single calendar window. Global biotech portfolios are repricing simultaneously across antibody-drug conjugate (ADC) and cell therapy franchises, a dynamic felt from New York to Tokyo to Zurich.
ADC franchises are no longer valued as single-drug assets. Investors globally are pricing them as industrial-scale development platforms — a structural shift that mirrors how European regulators have approached combination oncology approvals over the past three years.
Clinical data entering this cycle is broadly supportive. Venetoclax combined with obinutuzumab delivered a median time to next treatment of approximately eight years in previously untreated CLL patients — a durability outcome that outpaces standard chemotherapy globally and anchors long-term market positioning across US and EU markets.1
In small cell lung cancer, IMforte trial results support Zepzelca (lurbinectedin) in the first-line maintenance setting alongside immunotherapy. SCLC's aggressive post-chemotherapy progression makes first-line maintenance commercially critical — a priority shared by oncology systems in Europe, Japan, and South Korea.2
The supercycle extends beyond standard oncology. CASGEVY's pediatric sickle cell expansion, CNTY-813's iPSC-derived islet cell program for Type 1 diabetes, and selinexor's SENTRY trial in myelofibrosis represent platform-level validations — rare disease programs advancing in parallel with ADC pipelines, not behind them.3
R&D capital allocation is shifting globally. Companies are front-loading pipelines with external acquisitions before post-approval premiums close deal-making windows. Pipeline visibility extends to 2027, with ADC combination readouts and new registration studies expected — supporting a structural repricing thesis over a purely event-driven trade.
The primary risk is correlation. A single high-profile rejection can mark down an entire drug class, leaving multi-program ADC portfolios in the US, Europe, and Asia exposed to simultaneous drawdowns within a compressed timeline.
